Comparison of Safety and Efficacy of Intravitreal Ziv-Aflibercept Vs Bevacizumab for the Treatment of Macular Edema

Hussain Ahmad Khaqan¹, Usman Imtiaz², Hasnain Muhammad Buksh³
Hafiz Ateeq-ur-Rehman⁴, Raheela Naz⁵
¹-⁵Ameer-ud-Din Medical College PGMI, Lahore General Hospital, Lahore – Pakistan

ABSTRACT

Purpose: To study the safety and efficacy of intravitreal Ziv-Aflibercept vs. Bevacizumab for the management of edema caused by different retinal pathologies.

Study Design: Comparative interventional study.

Place and Duration of Study: Department of Ophthalmology, Unit II, Lahore General Hospital, Lahore, from July 2018 to June 2019.

Material and Methods: All patients with resistant, center involving macular edema due to diabetes, retinal vein occlusion and age related macular degeneration were recruited in this study. Complete baseline ocular examination was performed at presentation. All the patients were randomly grouped into two i.e. IVZ (intravitreal Ziv-Aflibercept) and IVB (intravitreal bevacizumab). Each eye underwent intravitreal injection of 0.05 ml of fresh filtered ziv-aflibercept (1.25 mg) or 0.05 ml of fresh filtered Bevacizumab. Outcome was measured in terms of variation in central macular thickness (CMT) and also best corrected visual acuity (BCVA) at 3 months.

Results: Total of 156 eyes of 136 patients completed whole duration of study and were included in the results. The mean baseline CMT was 510 μm (± 94 μm) in the IVB group and 493μm (±102 μm) in the IVZ group (P = 0.94). The mean baseline BCVA (log MAR) was 0.78 (Snellen's equivalent 6/36) in the IVZ and 0.70 (Snellen's equivalent 6/30) in the IVB group (P = 0.78). Central macular thickness was significantly reduced at 1st, 2nd and 3rd month in the IVZ group and IVB group (P < 0.001).

Conclusion: Intravitreal Ziv-Aflibercept is safe and more effective than Bevacizumab for the treatment of edema caused by diabetes mellitus, retinal vein occlusion and wet age related macular degeneration.

Key Words: Aflibercept, Ziv-Aflibercept, Bevacizumab, Diabetic Retinopathy, Wet Age related Macular degeneration, Retinal vein occlusion.


Doi: 10.36351/pjo.v36i3.1014

INTRODUCTION

Anti-vascular endothelial growth factor (VEGF) drugs have become the standard of care for several chorioretinal vascular conditions including wet age related macular degeneration (AMD), macular edema secondary to diabetes and retinal vein occlusions¹. First most common retinal vascular condition i.e. macular edema secondary to retinal vein occlusion results in considerable decrease in best corrected visual acuity (BCVA).² VEGF mediates the development of neovascularization in retinal vein
occlusion which results in severe irreversible vision loss.

The WESDR (Wisconsin Epidemiologic Study of Diabetic Retinopathy) found that there are 26% chances of developing DME after 14 years in type I diabetes, whereas Diabetes Control and Complication Trial (DCCT) reported that 27% of type I diabetics develop DME after 9 years. Type II diabetes in older patients is associated with higher incidence of macular edema. Retinal Ischemia promotes VEGF production, which in turns mediates the development of neovascularization in diabetic retinopathy and may lead to severe irreversible vision loss.

The basic problem in wet age related macular degeneration (AMD) leading to 1.6% of blindness of American population is abnormal neovascularization and vascular permeability. Positive regulators like vascular endothelial growth factor A (VEGF-A), transforming growth factor α and β (TGF α and β), fibroblast growth factor, hepatocyte growth factor, connective tissue growth factor and interleukins; and negative regulators: pigment epithelium-derived factor (PEDF), thrombostatin, angiostatin and endostatins play an important role in angiogenesis. Intraocular VEGF is reduced by the anti-VEGF agents administered in the eyes of patients, which reduces the vascular permeability and stops vascular leakage.

Ranibizumab was the first approved anti-VEGF agent that revolutionized DME treatment. Recently, newer anti-VEGF (vascular endothelial growth factor) drug, aflibercept (Eyelea®, Bayer Healthcare, Germany), approved by Food and Drug Administration (FDA), has shown good treatment outcomes, in patients with macular edema secondary to CRVO. Eyelea (Aflibercept) is approved therapy for macular edema caused by Age related macular degeneration, diabetes and retinal vein occlusion.

Ziv-aflibercept (Zaltrap; Regeneron, New York, USA) is pharmacologically similar to aflibercept, and the mechanism of action is also similar to Aflibercept i.e. it acts on all VEGF subtypes as well as placental growth factor. It is approved by FDA for the treatment of colon cancer, and is available at pharmacies much cheaper than aflibercept particularly for ocular use. Toxicity to RPE (retinal pigment epithelial cells) has never been studied in previous studies by using approved cancer protein, ziv-aflibercept.

The aim of our study was to compare the efficacy and safety of intravitreal ziv-aflibercept with that of Bevacizumab for the treatment of edema caused by diabetes mellitus, RVO and wet AMD.

MATERIAL AND METHODS

A prospective, comparative interventional study was conducted in the Ophthalmology department, Unit II of Lahore General Hospital, Lahore from July 2018 to June 2019. Institutional Review Board approval was obtained and study followed tenets of declaration of Helsinki. Informed consent was obtained from the patients. All patients with only eye, uncontrolled diabetes, uncontrolled hypertension, advanced cataract, uncontrolled glaucoma, epiretinal membrane (ERM) or vitreous traction and prior intervention with laser and intravitreal injection were excluded from the study.

Complete baseline ocular examination was performed at presentation including best corrected visual acuity (BCVA), anterior segment examination, posterior segment examination and indirect ophthalmoscopy, intra-ocular pressure assessment, OCT and FFA (optical coherence tomogram and fundus fluorescein angiography respectively). BCVA was performed using Snellen’s visual acuity chart and also using Log MAR scale. The OCT was performed using Cirrus 5000 (Zeiss, Dublin, CA). Thickness of central retina was measured in a 3 mm circle centered on point of fixation. Central 1 mm zone was taken as central macular thickness (CMT).

All the patients that fulfilled the inclusion and exclusion criteria were assigned to one of the two different treatment groups randomly: 1.25 mg (0.05 ml) of Ziv-aflibercept (ZALTRAP; Regeneron Pharmaceuticals Inc) (IVZ group) and 1.25 mg (0.05 ml) of Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA) (IVB group). Randomization was performed using random number table. Participants and the investigators were masked of the study groups. Surgeries other than the study investigators performed all the interventions.

After taking aseptic measures, each eye received intravitreal injection of 0.05 ml of filtered ziv-aflibercept (1.25 mg) or 0.05 ml of fresh filtered Bevacizumab in the operation theater. 30-gauge tuberculin syringes were used to deliver the injection under topical anesthesia. All eyes underwent slit-lamp
examination at 1st and 7th post-operative day to look for any intra-ocular inflammation and raised intra-ocular pressure. Minimum of three doses were given to all the participants at 4 weekly intervals. BCVA, slit lamp assessment and Optical Coherence Tomography were performed again at 1st, 2nd, 3rd and 6th months.

Measurement of change in CMT (central macular thickness) and BCVA (best corrected visual acuity) at 3rd month was the primary outcome. Secondary outcome measures were change in BCVA and CMT at 1st, 2nd and 6th month. Any potential eye related and systemic complications related to the intervention were assessed at each follow-up visit.

RESULTS

Primarily 162 eyes of 141 patients satisfied our inclusion and exclusion criteria. Of this 5 patients (7 eyes) were lost to follow-up. So total of 156 eyes of 136 patients completed whole duration of study and were included in the results. IVZ group included 70 patients (81 eyes) and IVB group had 66 patients (75 eyes). Twenty patients had bilateral injections.

Table 1 shows demographic data. Two groups carry no difference regarding demographic and baseline features. The mean baseline central macular thickness was 510 µm (±94 µm) in the intravitreal bevacizumab group and 493 µm (±102 µm) in the intravitreal ziv-afiblercept group (P = 0.94). The mean baseline BCVA (logMAR) was 0.78 (Snellen’s equivalent 6/36) in the IVZ and 0.70 (Snellen’s equivalent 6/30) in the IVB group (P = 0.78).

There was significant improvement in the best corrected visual acuity (BCVA) after every 1 month interval in both groups (P < 0.001). At 3rd month best corrected visual acuity difference was significant among the groups. Intravitreal ziv-afiblercept group showed significant changes in the best corrected visual acuity (BCVA) as compared to intravitreal bevacizumab group (Table 2 and Fig 1).

Table 2: Comparison of Visual acuity at 1st, 2nd and 3rd month.

<table>
<thead>
<tr>
<th></th>
<th>Total (n=156)</th>
<th>IVZ (n=70)</th>
<th>IVB (n=75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline BCVA</td>
<td>0.74 ± 0.21</td>
<td>0.78 ± 0.22</td>
<td>0.70 ± 0.21</td>
</tr>
<tr>
<td>Change 8 Weeks</td>
<td>0.36 ± 0.16</td>
<td>0.30 ± 0.19</td>
<td>0.48 ± 0.21</td>
</tr>
<tr>
<td>Change 4 Weeks</td>
<td>0.52 ± 0.19</td>
<td>0.48 ± 0.17</td>
<td>0.56 ± 0.15</td>
</tr>
<tr>
<td>Change 12 Weeks</td>
<td>0.45 ± 0.12</td>
<td>0.42 ± 0.13</td>
<td>0.48 ± 0.11</td>
</tr>
</tbody>
</table>

Fig 1: Graph showing BCVA during the course of study.

In comparison to the baseline values, central macular thickness decreased significantly at 1st, 2nd, and 3rd month in the IVZ group and IVB group (P < 0.001). Overall, in all visits, CMT was much reduced in the IVZ group in comparison to the IVB group (Table 3 and Fig. 2). At 24 weeks follow-up, BCVA and CMT were significantly improved in both treatment arms (P < 0.001). BCVA changes were significantly better in the IVZ group as compared to the IVB group.

In our study, in IVZ group, 3 eyes experienced sterile intraocular inflammation while 2 eyes showed significant progression of cataract.
DISCUSSION
Limited data is available which compares the safety profiles and efficacy of ziv- aflibercept anti-vascular endothelial growth factor (VEGF) drug with other commonly used agents. Oliveira Dias et al stated that there were no changes in ERG in patients with AMD who received intravitreal ziv-aflibercept showing no toxicity to retinal tissue and there was visual and OCT improvements seen in the patients. Intraocular inflammation was observed in one of the eyes and the inflammation resolved after taking appropriate therapy 11. De Andrade G et al conducted a study in which they injected intravitreal ziv-aflibercept in seven patients with macular edema due to diabetes. They studied the safety and efficacy of ziv-aflibercept over 48 weeks period and concluded that the drug was safe and effective 12.

Another study conducted by Singh et al constituted the largest pooled safety report on IVZ use and included patients from 14 centres distributed across the globe. It showed that IVZ had an acceptable ocular and systemic safety profile with incidence of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supported the continued use of IVZ in various retinal disorders 13.

Papadopoulos et al compared two different doses of Ziv-aflibercept with other anti-VEGF in treating wet Age related macular degeneration. They followed the patients for 16-weeks and concluded that both doses of Ziv-aflibercept were superior to Bevacizumab in terms of final BCVA and CMT 14.

Baghi et al compared two different doses of Zaltrap with Avastin for the management of macular edema due to diabetes. They followed the patients for 12-weeks and concluded that both doses of ziv-aflibercept were superior to Bevacizumab in terms of final BCVA and CMT 15.

In one study of intravitreal injections of ziv aflibercept for DME, a prospective single-treatment clinical trial, demonstrated that ziv-aflibercept monotherapy was linked with substantial improvement in mean BCVA and CMT in a 24-week follow-up. There was also no ERG evidence of retinal toxic reactions after intravitreal ziv-aflibercept injections in eyes with DME 16.

Cost is a major factor when it comes to selecting anti-VEGF for the treatment of macular edema. Most of these patients require monthly injections and this can add up to a huge amount of money. Compounded intravitreal Bevacizumab and Ziv-aflibercept costs around USD 50 per dose, which is 15-20 times less than the cost of Ranibizumab or Aflibercept 17.

One study showed that use of Aflibercept instead of Bevacizumab has lead to overspending of about €335 million in one year in Europe 18. So Ziv-aflibercept can prove to be a very valuable agent for the treatment of macular edema especially in under-developed and developing countries where insurance covering is scarce. One of the major concerns for compounded intravitreal injections is the risk of endophthalmitis 19.

Both aflibercept and ziv-aflibercept are structurally similar containing the same fusion protein, but there are few differences like in the osmolarity. 300 mOsm/kg is the osmolarity of aflibercept which is iso-osmotic solution and 1000 mOsm/kg is the osmolarity of ziv-aflibercept which is more concentrated. In addition, the 0.05ml of ziv-aflibercept contains 1.25 mg whereas aflibercept contains 2.0 mg.
In our study we demonstrated intermediate term outcomes, which were in favour of ziv-aflibercept. At all follow-ups, BCVA was significantly better in patients who received ziv-aflibercept as compared to those who received Bevacizumab. Similarly, better CMT reduction was achieved in ziv-aflibercept group than in Bevacizumab group.

Ziv-aflibercept shares the same molecular structure as aflibercept. However, the manufacturing process of aflibercept involves more robust purification and use of buffers to reduce the ocular irritation and toxicity\textsuperscript{20}. In our study 3 eyes (3.7\%) demonstrated sterile intraocular inflammation in ziv-aflibercept group. This is significant and difference in manufacturing process of ziv-aflibercept may explain this incidence. All of the three patients were managed medically and none of them had reduction in final BCVA as compared to than baseline. Ziv-aflibercept is prepared in laboratory with slightly hypertonic sucrose, which damages the lens and retina, it causes mild mitochondrial toxicity in human RPE cells\textsuperscript{8}. In our study however, we did not experience any case of retinal toxicity but in 2 eyes (2.5\%) there was significant cataractar progression.

Limitations of our study include small sample size and relatively shorter follow-up period. Long term outcomes and complications need to be addressed by having a larger patient pool and longer duration of follow-ups.

CONCLUSION
Intravitreal ziv-aflibercept is more effective than Bevacizumab for the treatment of diabetic macular edema. However, complications like sterile intraocular inflammation and cataract progression caused by intravitreal ziv-aflibercept needs to be investigated in detail.

Acknowledgement
This study was funded by the OSP research fund.

Ethical Approval
The study was approved by the Institutional review board/Ethical review board.

Conflict of Interest
Authors declared no conflict of interest

Authors’ Designation and Contribution
Hussain Ahmad Khaqan; Associate Professor: Study conception, Study Design, Manuscript Revision.
Usman Imtiaz; Vitreoretinal Fellow: Manuscript writing, Data Analysis, Critical Revision.
Hasnain Muhammad Buksh; Vitreoretinal Fellow: Manuscript writing, Literature Review, Study Design.
Hafiz Ateeq-ur-Rehman; Post Graduate Resident: Data collection, Data Analysis, Proofreading.
Raheela Naz; Post Graduate Resident: Data collection, Literature Review, Proofreading.

REFERENCES

---